High Tech Pharm Co

High Tech Pharm Co CROIC

The Cash Return on Invested Capital (CROIC) of High Tech Pharm Co (106190.KQ) as of Nov 5, 2026 is 11.56 %. In the previous year, Cash Return on Invested Capital (CROIC) was 9.83 % — a change of 17.56% (higher).

CROIC

11.56 %

YoY

17.56%

Last updated:

Cash Return on Invested Capital (CROIC) of High Tech Pharm Co is 2025 11.56 % . Cash Return on Invested Capital (CROIC) of High Tech Pharm Co was 2024 9.83 % . It decreases by 17.56% higher compared to the previous year.

The High Tech Pharm Co CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-3.24 KRW
Jan 1, 2019
0.30 KRW
Jan 1, 2020
-8.17 KRW
Jan 1, 2021
5.52 KRW
Jan 1, 2022
-3.75 KRW
Jan 1, 2023
-1.77 KRW
Jan 1, 2024
9.83 KRW
Jan 1, 2025
11.56 KRW
The High Tech Pharm Co CROIC history
YEARCROICYoY
11.56 %+17.56%
9.83 %-656.26%
-1.77 %-52.82%
-3.75 %-167.82%
5.52 %-167.62%
-8.17 %-2,835.41%
0.30 %-109.22%
-3.24 %-42.68%
-5.65 %-73.72%
-21.51 %+208.98%
-6.96 %-941.41%
0.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

High Tech Pharm Co Stock analysis

What does High Tech Pharm Co do? High Tech Pharm Co., Ltd. generates revenue by manufacturing and selling raw materials specifically for injectable antibiotic products. The company's product portfolio consists of sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem, and other related pharmaceutical ingredients. These items are produced for use in the medical sector as active pharmaceutical components. The firm sells these antibiotic pharmaceutical ingredients to both domestic and overseas markets. As a Korea-based entity, it distributes its sterile products to buyers who require raw materials for injectable formulations. The company operates from its headquarters in Chungju, Chungcheongbuk-Do, where it utilizes its workforce to support this manufacturing and distribution model. High Tech Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about High Tech Pharm Co stock

Cash Return on Invested Capital (CROIC) of High Tech Pharm Co is 11.56 % in 2025.

Cash Return on Invested Capital (CROIC) of High Tech Pharm Co changed from 9.83 % to 11.56 %, representing a 17.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) High Tech Pharm Co since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s High Tech Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — High Tech Pharm Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — High Tech Pharm Co